iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, Australia and internationally. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, insomnia and other conditions. The company is also developing Wafermine, a racemic ketamine sublingual wafer, which has completed phase-2 clinical trial for the treatment of complex regional pain syndrome, as well as psychiatric conditions, including depression; iXB 401, a sublingual semaglutide wafer that is in pre-clinical development for the treatment of Type 2 Diabetes and Obesity; SL-NAD+, a sublingual NAD+ wafer to increase the body's NAD+ levels, energy levels, and alertness. In addition, it develops BnoX that is in a phase-1 clinical trial for moderate to severe pain; NAD+ for sarcopenia; and LumeniX, a sublingual glutathione wafer for skin brightening and immunity. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.
Research context
IX BIOPHARMA LTD. appears in PyInvesting’s Singapore Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- SGD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
iX Biopharma Ltd is currently in a long term downtrend where the price is trading 4.5% below its 200 day moving average.
From a valuation standpoint, the stock is 1143.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 105.4.
iX Biopharma Ltd's total revenue rose by 182.3% to $830K since the same quarter in the previous year.
Its net income has increased by 51.2% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 8.9% to $-3M since the same quarter in the previous year.
Based on the above factors, iX Biopharma Ltd gets an overall score of 3/5.